Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Mar;69(3):313-322.
doi: 10.1002/acr.22944.

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis

Brian C Sauer  1 , Chia-Chen Teng  1 , Derek Tang  2 , Jianwei Leng  1 , Jeffrey R Curtis  3 , Ted R Mikuls  4 , David J Harrison  2 , Grant W Cannon  1
Affiliations
Comparative Study

Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis

Brian C Sauer et al. Arthritis Care Res (Hoboken). 2017 Mar.

Abstract

Objective: To compare persistence and adherence to triple therapy with the nonbiologic disease-modifying antirheumatic drugs (DMARDs) methotrexate (MTX), hydroxychloroquine, and sulfasalazine, versus a tumor necrosis factor inhibitor (TNFi) plus MTX in patients with rheumatoid arthritis (RA).

Methods: Administrative and laboratory data were analyzed for US Veterans with RA initiating triple therapy or TNFi + MTX between January 2006 and December 2012. Treatment persistence 365 days postindex was calculated using 3 definitions. Definition 1 required no gap in therapy of ≥90 days for any drug in the original combination. Definition 2 required no added or switched DMARD, no decrease to nonbiologic DMARD monotherapy, and no termination of all DMARD therapies. Definition 3 was similar to definition 2 but allowed a switch to another drug within the same class. Adherence used a proportion of days covered of ≥80%. Propensity-weighted analysis with matched weights was used to balance covariates.

Results: The analysis included 4,364 RA patients (TNFi + MTX, n = 3,204; triple therapy, n = 1,160). In propensity-weighted analysis, patients in the TNFi + MTX group were significantly more likely than patients in the triple therapy group to satisfy all persistence criteria in definition 1 (risk difference [RD] 13.1% [95% confidence interval (95% CI) 9.2-17.0]), definition 2 (RD 6.4% [95% CI 2.3-10.5]), and definition 3 (RD 9.5% [95% CI 5.5-13.6]). Patients in the TNFi + MTX group also exhibited higher adherence during the first year (RD 7.2% [95% CI 3.8-10.5]).

Conclusion: US Veterans with RA were significantly more likely to be persistent and adherent to combination therapy with TNFi + MTX than triple therapy with nonbiologic DMARDs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Propensity score analysis with standardized difference scores before and after application of matched weights. VA = Veterans Affairs; NSAID = nonsteroidal antiinflammatory drug; CCS = Clinical Classification System; HIV = human immunodeficiency virus; RDCI = rheumatic disease comorbidity index; CCP  = cyclic citrullinated peptide; ED = emergency department.
Figure 2
Figure 2
Kaplan‐Meier plot for persistence with matching weights, definition 1: no gap in therapy of ≥90 days for any drug in the original combination. TNFi = tumor necrosis factor inhibitor; MTX = methotrexate. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/acr.22944/abstract.
Figure 3
Figure 3
Kaplan‐Meier plot for persistence with matching weights, definition 2: no added or switched disease‐modifying antirheumatic drug (DMARD), no decrease to nonbiologic DMARD monotherapy, and no termination of all DMARD therapies. TNFi = tumor necrosis factor inhibitor; MTX = methotrexate. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/acr.22944/abstract.
Figure 4
Figure 4
Kaplan‐Meier plot for persistence with matching weights, definition 3: similar to definition 2, but allowed a switch to another drug within the same class. TNFi = tumor necrosis factor inhibitor; MTX = methotrexate. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/acr.22944/abstract.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008;58:15–25. - PubMed
    1. Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001–2005. Arthritis Care Res (Hoboken) 2010;62:460–4. - PubMed
    1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84. - PubMed
    1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39. - PMC - PubMed
    1. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux‐Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources